{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-052736","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.462893+00:00","generated_at":"2026-06-08T04:39:52.425122+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocuphire Q3 net income $5.6M ($0.26 EPS); revenue $11.9M; FDA agrees Phase 3 endpoint for APX3330; RYZUMVI approved","bullets":["Q3 net income $5.6M ($0.26 basic EPS) vs $4.5M loss ($0.22 loss) a year ago; revenue $11.9M from $0.","Cash $42.4M; management believes sufficient into 2025.","Successful End-of-Phase 2 FDA meeting for APX3330; Phase 3 endpoint agreed (3-step worsening on DRSS).","RYZUMVI (phentolamine) FDA approved for mydriasis reversal; Ocuphire received $10M milestone from Viatris.","VEGA-2 Phase 3 presbyopia trial met primary endpoint; Viatris to continue Phase 3 development in 1H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-052736","json":"https://secwatch.observer/filing/0001140361-23-052736.json","markdown":"https://secwatch.observer/filing/0001140361-23-052736.md","text":"https://secwatch.observer/filing/0001140361-23-052736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123052736/0001140361-23-052736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123052736/ef20014551_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:39:52.425122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01b4651e5ee22e7472ac0949d0cb759a123053d7","claim":"Opus Genetics, Inc. reported third quarter ended September 30, 2023 results: revenue $11.9 million.","evidence_excerpt":"License and collaborations revenue was $11.9 million and $17.4 million for the three and nine months ended September 30, 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123052736/0001140361-23-052736-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$11.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}